Newsroom 2015 Playlist

Thermo Fisher Scientific Completes Acquisition of One Lambda

Category:

Dateline:

Public Company Information:

NYSE:

TMO

"One Lambda’s tests for tissue typing and antibody detection complement our existing immunosuppressant assays, allowing us to offer a broad menu of tests across the transplant-testing workflow. We are excited about this combination and the opportunities it presents to ultimately improve the lives of transplant patients."

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving
science, has completed its previously announced acquisition of One
Lambda, Inc., the leader in transplant diagnostics. Based in Canoga
Park, Calif., One Lambda has approximately 320 employees and had 2011
revenue of $182 million. The business will become part of Thermo
Fisher’s Specialty Diagnostics Segment.

“We are pleased to welcome One Lambda to our team and significantly
increase our access to the attractive transplant diagnostics market,”
said Marc N. Casper, president and chief executive officer of Thermo
Fisher Scientific. “One Lambda’s tests for tissue typing and antibody
detection complement our existing immunosuppressant assays, allowing us
to offer a broad menu of tests across the transplant-testing workflow.
We are excited about this combination and the opportunities it presents
to ultimately improve the lives of transplant patients.”

Thermo Fisher reiterated its expectation that the One Lambda transaction
will be accretive to 2012 adjusted earnings per share (EPS) and that it
will add $0.09 to $0.11 to the company’s 2013 adjusted EPS results.
Based upon the timing of the close, the transaction will have an
immaterial impact on Thermo Fisher’s third quarter adjusted EPS. The
company will provide updated guidance for 2012 when it reports its third
quarter 2012 financial results.

Use of Non-GAAP Financial Measures

In addition to the financial measures prepared in accordance with
generally accepted accounting principles (GAAP), we use certain non-GAAP
financial measures, including adjusted EPS, which excludes restructuring
and other costs/income and amortization of acquisition-related
intangible assets, certain other gains and losses, tax
provisions/benefits related to the previous items, benefits from tax
credit carryforwards, the impact of significant tax audits or events and
discontinued operations. We exclude the above items because they are
outside of our normal operations and/or, in certain cases, are difficult
to forecast accurately for future periods. We believe that the use of
non-GAAP measures helps investors to gain a better understanding of our
core operating results and future prospects, consistent with how
management measures and forecasts the company's performance, especially
when comparing such results to previous periods or forecasts.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE:TMO) is the world leader in serving
science. Our mission is to enable our customers to make the world
healthier, cleaner and safer. With revenues of $12 billion, we have
approximately 39,000 employees and serve customers within pharmaceutical
and biotech companies, hospitals and clinical diagnostic labs,
universities, research institutions and government agencies, as well as
in environmental and process control industries. We create value for our
key stakeholders through three premier brands, Thermo Scientific, Fisher
Scientific and Unity™ Lab Services, which offer a unique combination of
innovative technologies, convenient purchasing options and a single
solution for laboratory operations management. Our products and services
help our customers solve complex analytical challenges, improve patient
diagnostics and increase laboratory productivity. Visit www.thermofisher.com.

Safe Harbor Statement

The following constitutes a “Safe Harbor” statement under the Private
Securities Litigation Reform Act of 1995: This press release contains
forward-looking statements that involve a number of risks and
uncertainties. Important factors that could cause actual results to
differ materially from those indicated by such forward-looking
statements are set forth in the company’s Quarterly Report on Form 10-Q
for the quarter ended June 30, 2012, under the caption “Risk Factors,”
which is on file with the Securities and Exchange Commission and
available in the “Investors” section of our website under the heading
“SEC Filings.” Important factors that could cause actual results to
differ materially from those indicated by forward-looking statements
include risks and uncertainties relating to: the need to develop new
products and adapt to significant technological change; implementation
of strategies for improving growth; general worldwide economic
conditions, and related uncertainties; dependence on customers' capital
spending policies and government funding policies; the effect of
exchange rate fluctuations on international operations; the effect of
healthcare reform legislation; use and protection of intellectual
property; the effect of changes in governmental regulations; and the
effect of laws and regulations governing government contracts, as well
as the possibility that expected benefits related to the acquisition of
One Lambda may not materialize as expected; and the parties being unable
to successfully implement integration strategies. While we may elect to
update forward-looking statements at some point in the future, we
specifically disclaim any obligation to do so, even if estimates change
and, therefore, you should not rely on these forward-looking statements
as representing our views as of any date subsequent to today.